Abstract
Much work has been done to understand the molecular mechanisms underlying the inflammatory bowel diseases (IBD). IL-13 has emerged as an important cytokine effective in ulcerative colitis (UC) and fistulizing Crohn's disease (CD). IL-13 is a T helper 2-type cytokine with pleiotropic effects, involved in parasite expulsion, asthma pathophysiology, natural history of cancer and other human pathologies. Great interest has therefore been developed in inhibiting its function as a therapeutic intervention in these diseases.
The multifunctional properties of IL-13, with particular emphasis on its role in both CD and UC, as well as current developing pharmacologic agents inhibiting the IL-13 signaling pathway have been reviewed. Anti-IL-13 agents seem to be promising therapeutic strategies for the future management of IBD and other human diseases.
Keywords: Crohn's disease, inflammatory bowel disease, interleukin-13, lebrikizumab, pleiotropic, tralokinumab, ulcerative colitis.
Current Drug Targets
Title:Anti-IL-13 in Inflammatory Bowel Disease: From the Bench to the Bedside
Volume: 14 Issue: 12
Author(s): Manol Jovani, Gionata Fiorino and Silvio Danese
Affiliation:
Keywords: Crohn's disease, inflammatory bowel disease, interleukin-13, lebrikizumab, pleiotropic, tralokinumab, ulcerative colitis.
Abstract: Much work has been done to understand the molecular mechanisms underlying the inflammatory bowel diseases (IBD). IL-13 has emerged as an important cytokine effective in ulcerative colitis (UC) and fistulizing Crohn's disease (CD). IL-13 is a T helper 2-type cytokine with pleiotropic effects, involved in parasite expulsion, asthma pathophysiology, natural history of cancer and other human pathologies. Great interest has therefore been developed in inhibiting its function as a therapeutic intervention in these diseases.
The multifunctional properties of IL-13, with particular emphasis on its role in both CD and UC, as well as current developing pharmacologic agents inhibiting the IL-13 signaling pathway have been reviewed. Anti-IL-13 agents seem to be promising therapeutic strategies for the future management of IBD and other human diseases.
Export Options
About this article
Cite this article as:
Jovani Manol, Fiorino Gionata and Danese Silvio, Anti-IL-13 in Inflammatory Bowel Disease: From the Bench to the Bedside, Current Drug Targets 2013; 14 (12) . https://dx.doi.org/10.2174/13894501113149990170
DOI https://dx.doi.org/10.2174/13894501113149990170 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Adaptors in Toll-Like Receptor Signaling and their Potential as Therapeutic Targets
Current Drug Targets Spray-Dried Polymeric Nanoparticles for Pharmaceutics: A Review of Patents
Recent Patents on Drug Delivery & Formulation Emerging Mucus Regulating Drugs in Inflammatory and Allergic Lung Disease
Inflammation & Allergy - Drug Targets (Discontinued) Pharmacological Modulation of Th17
Recent Patents on Inflammation & Allergy Drug Discovery Immunological Properties of Donkeys Milk: Its Potential Use in the Prevention of Atherosclerosis
Current Pharmaceutical Design Musculoskeletal Adverse Drug Reactions: A Review of Literature and Data from ADR Spontaneous Reporting Databases
Current Drug Safety Chiral Kinase Inhibitors
Current Topics in Medicinal Chemistry Perspectives of New Therapies for Endometriosis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Mechanism of Action of Methamphetamine within the Catecholamine and Serotonin Areas of the Central Nervous System
Current Drug Abuse Reviews Enteric Coated Guar Gum Microspheres of Ornidazole for Colonic Delivery
Current Nanoscience Strategies for Targeting IL-4 as a Novel Therapeutic Approach for the Treatment of Atopic Dermatitis
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents The Role of Chest High Resolution CT and RT-PCR in Diagnosis of Different Stages of Coronavirus (COVID-19) Pneumonia
New Emirates Medical Journal Characterization of a Novel Polysaccharide-Iron(III) Complex and Its Anti-Anemia and Nonspecific Immune Regulating Activities
Mini-Reviews in Medicinal Chemistry About Editor-in-Chief
Current Drug Discovery Technologies Does RSV Infection Alter the Course of Chronic Lung Disease in Prematurely Born Infants?
Current Respiratory Medicine Reviews Glycosaminoglycans and the Regulation of Allergic Inflammation
Current Drug Targets - Inflammation & Allergy Prostaglandins Pathway as a Possible Biological Link Between Cancer and Major Depression
Current Angiogenesis (Discontinued) Nanotheranostics in Evidence Based Personalized Medicine
Current Drug Targets Oxidative Stress in Allergic and Irritant Dermatitis: From Basic Research to Clinical Management
Recent Patents on Inflammation & Allergy Drug Discovery Resolution of Empyema Thoracis after Patient Refusal of Surgical Intervention: A Case Series and Review of the Literature
Current Respiratory Medicine Reviews